Cabal
2
2M
2
2.00
- Areas of investment
Investor highlights
- Stage focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Rounds per year
- 2.00
- Investments by industry
- FinTech (1)
- Financial Services (1)
- EdTech (1)
- Investments by region
- United States (2)
- Peak activity year
- 2022
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 1
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Deposits.com | 23 Aug 2022 | Financial Services, FinTech | Seed | 5M | United States, Texas, Dallas |
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Galux , a Seoul, South Korea-based biotech company developing an AI-driven protein therapeutics design, | Sep 2, 2026 | AI, AI-driven protein therapeutics design, Biotech, Drug design platform | - | 29000000 USD | Galux |
| Aniai | Jan 24, 2024 | AI Software, Cooking Solutions, Hamburger Cooking, Kitchen Solutions, Robotic | Early stage | 12000000 USD |  New York |
| SeaBeLife | Sep 26, 2023 | Biotechnology, Drug Development, Healthcare, Platform Technology | Early stage | 1200000 EUR |  Roscoff, Brittany |
| Phantom AI | Jan 2, 2023 | Autonomous Driving, Computer Vision, Sensor Fusion | Growth stage | 36500000 USD | Mountain View, California |
| PineTree Therapeutics | Aug 6, 2022 | Immuno-oncology, Oncology, Viral Diseases | Early stage | 23500000 USD | Cambridge, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.